Caribou is applying its next-generation CRISPR genome editing technology in the discovery and development of novel therapeutic candidates. Current areas of focus include genome-edited off-the-shelf allogeneic CAR-T cell and natural killer (NK) cell therapies for the treatment of patients with advanced malignancies.
R/R B-NHL: relapsed/refractory B cell non-Hodgkin lymphoma
R/R MM: relapsed/refractory multiple myeloma
R/R AML: relapsed/refractory acute myeloid leukemia
Current clinical trial
For more information on Caribou Biosciences’ clinical trial, please visit clinicaltrials.gov.